DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
13
06
2018
accepted:
14
07
2018
revised:
13
07
2018
pubmed:
30
9
2018
medline:
18
12
2019
entrez:
30
9
2018
Statut:
ppublish
Résumé
Müllerian adenosarcomas are biphasic epithelial-mesenchymal tumors with benign epithelial and malignant mesenchymal components. The sarcoma component may be low or high grade; the latter is often seen in the presence of stromal overgrowth, which correlates with worse clinical outcome. Heterologous differentiation may also occur, usually in association with stromal overgrowth. DICER1 mutations have been reported primarily in a small subset of adenosarcomas with rhabdomyosarcomatous elements, but whether these are specific to the rhabdomyosarcomatous phenotype is unclear. In this study, we examined the clinical, pathologic, and genomic features of 19 müllerian adenosarcomas enriched for tumors with rhabdomyosarcomatous differentiation, as well as eight uterine carcinosarcomas with a rhabdomyosarcoma component. Somatic hotspot mutations in the RNase IIIb domain of DICER1 were identified in 8/19 (42%) adenosarcomas, of which four showed rhabdomyosarcomatous differentiation. DICER1 mutations were detected in 4/6 (67%) cases with a rhabdomyosarcoma component and in 4/11 (36%) cases without rhabdomyosarcoma. At least two DICER1 mutations were identified in 7/8 (88%) tumors, of which four had a truncating mutation. The hotspot DICER1 mutation in the remaining tumor was hemizygous and associated with loss of heterozygosity. Other less frequent recurrent somatic pathogenic alterations included Ras or PI3K/PTEN pathway aberrations (5/19 each, 26%), CDK4/MDM2 amplifications (3/19, 16%), and mutations in TP53 (3/19) and ARID1A (3/19). Two tumors demonstrated homozygous BAP1 deletion. One tumor harbored an ESR1-NCOA3 fusion gene. Carcinosarcomas with rhabdomyosarcomatous differentiation showed frequent mutations in TP53 (7/8, 88%) and the PI3K/PTEN pathway (6/8, 75%) but lacked DICER1 mutations. The findings highlight the importance of DICER1 mutations in müllerian adenosarcoma tumorigenesis and show that these alterations are not exclusive to heterologous rhabdomyosarcomatous differentiation.
Identifiants
pubmed: 30266945
doi: 10.1038/s41379-018-0132-5
pii: S0893-3952(22)00136-3
doi:
Substances chimiques
DICER1 protein, human
EC 3.1.26.3
Ribonuclease III
EC 3.1.26.3
DEAD-box RNA Helicases
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280-289Références
Eichhorn JH, Young RH, Clement PB, et al. Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26:1243–58.
doi: 10.1097/00000478-200210000-00001
Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21:363–81.
doi: 10.1016/0046-8177(90)90198-E
McCluggage WG. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol. 2010;17:122–9.
doi: 10.1097/PAP.0b013e3181cfe732
Hodgson A, Amemiya Y, Seth A, et al. High-grade mullerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior. Am J Surg Pathol. 2017;41:1513–22.
doi: 10.1097/PAS.0000000000000907
Howitt BE, Sholl LM, Dal Cin P, et al. Targeted genomic analysis of mullerian adenosarcoma. J Pathol. 2015;235:37–49.
doi: 10.1002/path.4442
Piscuoglio S, Burke KA, Ng CK, et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol. 2016;238:381–8.
doi: 10.1002/path.4675
Foulkes WD, Priest JR, et al. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014;14:662–72.
doi: 10.1038/nrc3802
Conlon N, Schultheis AM, Piscuoglio S, et al. A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Mod Pathol. 2015;28:1603–12.
doi: 10.1038/modpathol.2015.115
Dehner LP, Jarzembowski JA, Hill DA. Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations. Mod Pathol. 2012;25:602–14.
doi: 10.1038/modpathol.2011.185
Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–95.
doi: 10.1093/bioinformatics/btp698
Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Prot. 2015;10:1556–66.
doi: 10.1038/nprot.2015.105
Rausch T, Zichner T, Schlattl A, et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28:i333–9.
doi: 10.1093/bioinformatics/bts378
DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.
doi: 10.1038/ng.806
Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:1–33.
Ye K, Schulz MH, Long Q, et al. A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25:2865–71.
doi: 10.1093/bioinformatics/btp394
Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.
doi: 10.1093/bioinformatics/btp352
Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907 [q-bio.GN]. Available from: http://arxiv.org/abs/1207.3907 .
Picard: A set of tools (in Java) for working with next generation sequencing data in the BAM: Broad Institute. http://broadinstitute.github.io/picard .
McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.
doi: 10.1101/gr.107524.110
Street B, du Toit JP. Uterine adenosarcoma: report of a case with two further primary malignant tumors. Gynecol Oncol. 1981;11:252–8.
doi: 10.1016/S0090-8258(81)80018-2
Witkowski L, Mattina J, Schonberger S, et al. DICER1 hotspot mutations in non-epithelial gonadal tumours. Br J Cancer. 2013;109:2744–50.
doi: 10.1038/bjc.2013.637
Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 2012;366:234–42.
doi: 10.1056/NEJMoa1102903
Chen J, Wang Y, McMonechy MK, et al. Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. J Pathol. 2015;237:215–25.
doi: 10.1002/path.4569
Mullen MM, Divine LM, Hagemann IS, et al. Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report. Gyn Oncol Rep. 2017;20:121–4.
Wu MK, Sabbaghian N, Xu B, et al. Biallelic DICER1 mutations occur in Wilms tumours. J Pathol. 2013;230:154–64.
doi: 10.1002/path.4196
Wang Y, Chen J, Yang W, et al. The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors. Neoplasia. 2015;17:650–60.
doi: 10.1016/j.neo.2015.08.003
Jin Y, Moller E, Nord KH, et al. Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15; q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer. 2012;51:510–20.
doi: 10.1002/gcc.21939
Wang L, Motoi T, Khanin R, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012;51:127–39.
doi: 10.1002/gcc.20937
Mosquera JM, Sboner A, Zhang L, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52:538–50.
doi: 10.1002/gcc.22050
Hartmaier RJ, Trabucco SE, Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Annals Oncol. 2018;29:872–80.
Machida YJ, Machida Y, Vashisht AA, et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 2009;284:34179–88.
doi: 10.1074/jbc.M109.046755
Yu H, Pak H, Hammond-Martel I, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA. 2014;111:285–90.
doi: 10.1073/pnas.1309085110
Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature. 2010;465:243–7.
doi: 10.1038/nature08966
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disc. 2012;2:401–4.
doi: 10.1158/2159-8290.CD-12-0095
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
doi: 10.1126/scisignal.2004088
Luchini C, Veronese N, Yachida S, et al. Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis. Genes Chromosomes Cancer. 2016;55:741–9.
doi: 10.1002/gcc.22381
Wang XY, Wang Z, Huang JB, et al. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer. Tum Biol. 2017;39:1010428317699111.